Influence of psychiatric disorders and opioid substitution therapy on hepatitis C treatment with direct-acting antivirals in people who inject drugs.

Autor:	Fernández de Cañete Camacho JC; Servicio de Aparato Digestivo, Complejo Hospitalario Universitario de Albacete, Albacete, España. Electronic address: josecarlosfdcc@gmail.com., Mancebo Martínez A; Servicio de Aparato Digestivo, Complejo Hospitalario Universitario de Albacete, Albacete, España., García Mena MA; Servicio de Quirófano, Hospital General de Almansa, Almansa, Albacete, España., Moreno Planas JM; Servicio de Aparato Digestivo, Complejo Hospitalario Universitario de Albacete, Albacete, España; Universidad de Castilla-La Mancha, Albacete, España.
Jazyk:	English; Spanish; Castilian
Zdroj:	Gastroenterologia y hepatologia [Gastroenterol Hepatol] 2022 Apr; Vol. 45 (4), pp. 265-273. Date of Electronic Publication: 2021 Sep 17.
DOI:	10.1016/j.gastrohep.2021.09.003
Abstrakt:	Introduction: The effectiveness of the hepatitis C virus (HCV) treatment seems to be lower in people who inject drugs (PWID). We analyze the influence of various factors as psychiatric disorders and opioid substitution therapy (OST) on the treatment with direct-acting antivirals (DAA) in this collective. Patients and Methods: Three hundred thirty-two PWID patients were treated with DAA in 12 Spanish hospitals between 2004 and 2020. They were catalogued in recent and former consumers (if the last consumption was in the last 3 years) and several variables were included, evaluating the effectiveness of the treatment according to the viral load 12 weeks after the end of the treatment with the parameter «sustained viral response» (SVR12). Results: 23.4% were recent consumers and 27.7% were on OST. The 41.5% had any diagnosis of psychiatric disorder. SVR12 was 84.04%, ascending to 96.21% when excluded from the analyses the patients lost to follow-up (12.7%). SVR12 was lower due to an increase in the loss to follow-up in recent consumers and other factors like OST, being in prison the last 5 years, naïve patients, generalized anxiety disorder and benzodiazepine consumption. Conclusions: The effectiveness of the HCV treatment with DAA in PWID is similar than in general population in patients whit an appropriate follow-up. It is important to maintain a closer follow-up in patients on OST, recent consumers and those with psychiatric disorders. (Copyright © 2021 Elsevier España, S.L.U. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu